Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

2 results
12:00 AM, Jun 27, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

MDX-1097: Phase II ongoing

Squibb Co. (NYSE:BMY), New York, N.Y.   Product: MDX-1097   Business: Cancer   Molecular target: Kappa myeloma antigen
KMA)   Description: Human IgG1k chimeric mAb that induces antibody dependent cellular cytotoxicity (ADCC) through NK …
12:00 AM, Apr 27, 2009  |  BC Week In Review | Clinical News  |  Clinical Status

MDX-1097: Phase I started

  Medarex Inc. (NASDAQ:MEDX), Princeton, N.J.   Product: MDX-1097   Business: Cancer   Molecular target: Kappa myeloma antigen
KMA)   Description: Human IgG1k chimeric monoclonal antibody that induces antibody dependent cellular cytotoxicity (ADCC) through …